DZ Bank upgraded Gilead (GILD) to Buy from Hold with a $108 price target Maximize Your Portfolio with Data Driven Insights:Leverage the power ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

The CNN Fear and Greed Index improved to Neutral zone on Monday with the overall market sentiment improving. U.S. stocks closed higher, led by tech gains.

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after ...

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

The stock's fall snapped a two-day winning streak.